An observational study in Cancer of Esophagus and Gastric Cancer, sponsored by Vastra Gotaland Region. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2020-07-28.
Sponsored by Vastra Gotaland Region · Observational
The occurrence of dysphagia is a well-known early feature of esophageal cancer that may reduce caloric intake and thus cause weight loss. Sarcopenia is considered to be a consequence of such involuntary nutritional restriction. The prevalence of sarcopenia in patients with esophageal cancer before and after surgery is not well known and its possible consequences have been debated.
Aim: The aim of this study was to prospectively explore body composition and function in a cohort of patients with esophageal cancer before and after surgery with curative intent. In particular, to investigate the prevalence and development of sarcopenia and body composition as a consequence to surgery for esophageal cancer and the possible relation to morbidity, length of stay and quality of life (QoL).
Methods: In a cohort of 76 patients who had esophageal- or cardia-cancer and were planned for surgery with a curative intent, data on body-composition measured with bioimpedance, working capacity (cardiac stress test), grip strength and QoL (European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 version 3.0) were prospectively collected. Data regarding dysphagia was derived from an esophagus related quality of life form (EORTC QLQ-OES18). Data on tumour stage and type, complications, length of stay and preoperative weight loss were collected from medical charts.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's enrollment of 76 is below the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Vastra Gotaland Region is the lead sponsor of 267 studies on the registry; 107 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study was a prospective collected cohort study in 76 patients who were referred to the surgery clinic at the Sahlgrenska University hospital 2005-2010. Patients with esophageal cancer or cancer of the gastroesophageal junction (Siewert I or II), who were scheduled to undergo resection surgery with curative intent, were asked to participate. Patients were excluded if they were found to have an advanced tumour stage or if they declined participation.
Exclusion Criteria:
Changes in Body composition after surgery for esophageal cancer with curative intent.
Body mass index (BMI) kg/m2
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent
Weight kg
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent.
Fat free mass (FFM) kg;
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent.
Fat mass (FM) kg;
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent.
Lean tissue mass (LTM) kg;
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent.
Total body water (TBW) l;
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent.
Intra cellular water (ICW) l;
Time frame: Three months
Changes in Body composition after surgery for esophageal cancer with curative intent.
Extra cellular water (ECW) l
Time frame: Three months
Changes in QoL (linear scale 0-100)
Time frame: From surgery up to three months
Changes in dysphagia (linear scale 0-100)
Time frame: From surgery up to three months
Length of stay (days)
Time frame: From surgery up to three months
Complications after surgery (Clavien-Dindo scale 0-5)
Time frame: From surgery up to three months
Mortality
Time frame: Length of survival after surgery
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vastra Gotaland Region